Immune Checkpoint Therapy and the Search for Predictive Biomarkers

被引：30

作者：

Sharma, Padmanee ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1155 Pressler St,Unit 1374,CPB7-3504, Houston, TX 77030 USA

来源：

CANCER JOURNAL | 2016年 / 22卷 / 02期

关键词：

Biomarkers; cancer; driver mutations; immune checkpoint therapy; CELL LUNG-CANCER; CTLA-4; BLOCKADE; T-CELLS; ANTITUMOR IMMUNITY; ADVANCED MELANOMA; PD-1; ANTI-PD-L1; ANTIBODY; ANTI-CTLA-4; THERAPY; UNTREATED MELANOMA; CLINICAL ACTIVITY;

D O I：

10.1097/PPO.0000000000000185

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint therapy has started a revolution in the field of oncology. The concept that the immune systemplays a critical role in antitumor responses, which has been around for decades, has finally been proven and firmly established with elegant preclinical studies and dramatic clinical responses in patients as a result of antibodies that block inhibitory T-cell pathways. However, the clinical responses being achieved are only in a subset of patients, and more work is needed to provide a better understanding of the mechanisms that elicit tumor rejection, which will enable identification of appropriate biomarkers, reveal new targets, provide data to guide combination studies, and eventually dictate a platform that allows more patients to derive clinical benefit, including cures, with immune checkpoint therapy.

引用

页码：68 / 72

页数：5

共 54 条

[1]

ALLISON JP, 1982, J IMMUNOL, V129, P2293

[2] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). [J].

Amin, Asim ;

Plimack, Elizabeth R. ;

Infante, Jeffrey R. ;

Ernstoff, Marc S. ;

Rini, Brian I. ;

McDermott, David F. ;

Knox, Jennifer J. ;

Pal, Sumanta Kumar ;

Voss, Martin Henner ;

Sharma, Padmanee ;

Kollmannsberger, Christian K. ;

Heng, Daniel Yick Chin ;

Spratlin, Jennifer L. ;

Shen, Yun ;

Kurland, John F. ;

Gagnier, Paul ;

Hammers, Hans J. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[3] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[7]

Callahan MK, 2014, J CLIN ONCOL, P32

[8] Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial [J].

Carthon, Bradley C. ;

Wolchok, Jedd D. ;

Yuan, Jianda ;

Kamat, Ashish ;

Tang, Derek S. Ng ;

Sun, Jingjing ;

Ku, Geoffrey ;

Troncoso, Patricia ;

Logothetis, Christopher J. ;

Allison, James P. ;

Sharma, Padmanee .

CLINICAL CANCER RESEARCH, 2010, 16 (10) :2861-2871

[9] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[10] CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy [J].

Chen, Hong ;

Fu, Tihui ;

Suh, Woong-Kyung ;

Tsavachidou, Dimitra ;

Wen, Sijin ;

Gao, Jianjun ;

Tang, Derek Ng ;

He, Qiuming ;

Sun, Jingjing ;

Sharma, Padmanee .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :167-176

← 1 2 3 4 5 6 →